Development

Genco Shipping & Trading Appoints Paramita Das to Board of Directors

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today announced the appointment of Paramita Das to its Board of Directors effective immediately.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today announced the appointment of Paramita Das to its Board of Directors effective immediately.
  • With her appointment, the Board will comprise seven directors.
  • Ms. Das brings significant global leadership experience in the commodities sector.
  • Ms. Das currently serves on the Board of Coeur Mining, Inc.
    “Paramita is a highly respected global leader who brings a deep understanding of the commodities markets, which are vital to Genco, as well as further diversity to our Board,” said James G. Dolphin, Chairman of the Board.

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Retrieved on: 
Tuesday, March 5, 2024

NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.

Key Points: 
  • NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.
  • Resmetirom is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH.
  • The clinical development program for resmetirom is comprised of 18 clinical studies supporting the MAA: twelve Phase 1 studies, two Phase 2 studies, and four Phase 3 studies.
  • Without treatment, the disease can lead to cirrhosis, liver failure, liver cancer and premature death,” said Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal.

Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract

Retrieved on: 
Tuesday, March 5, 2024

Anthrax (B. anthracis) is an infectious disease caused by gram-positive, rod-shaped, spore-forming bacteria that can lead to severe illness and death.

Key Points: 
  • Anthrax (B. anthracis) is an infectious disease caused by gram-positive, rod-shaped, spore-forming bacteria that can lead to severe illness and death.
  • Oral NUZYRA tablets associated with this procurement were manufactured in the United States as part of the company’s U.S. onshoring efforts.
  • “This procurement also represents a significant milestone in the company’s onshoring efforts as for the first time Paratek is providing BARDA with NUZYRA tablets produced on U.S. soil.
  • In December 2019, BARDA awarded Paratek a contract (75A50120C00001) that is now valued at up to approximately $304 million.

AB INTL Reports Forecast Revenues from Its Participated Chinese Market Film Sales

Retrieved on: 
Monday, March 4, 2024

AB reports excellent sales exceeding revenue forecasts for 2024 to date and release subsequent impressive annual future revenue projections.

Key Points: 
  • AB reports excellent sales exceeding revenue forecasts for 2024 to date and release subsequent impressive annual future revenue projections.
  • This forecast reflects AB's confidence in its strategic direction and its unwavering commitment to delivering sustainable growth and shareholder value.
  • With a concerted effort to broaden its business partners base and enhance operational efficiency, AB is positioned to accelerate revenue growth.
  • 2024 is destined to be full of substantial updates as AB continues to execute its growth and expansion strategy.

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Retrieved on: 
Monday, March 4, 2024

Dr. Jenkins’ esteemed career spans more than 25 years in the global pharmaceutical, biotechnology and life science industry.

Key Points: 
  • Dr. Jenkins’ esteemed career spans more than 25 years in the global pharmaceutical, biotechnology and life science industry.
  • Dr. Jenkins currently provides board level and consulting services to organizations across the life science and healthcare industry.
  • As a pharmaceutical thought leader, Dr. Jenkins routinely contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.
  • “We are delighted to have someone of Dr. Annalisa Jenkins’ caliber join the board of Skye,” said Punit Dhillon, CEO and Chair of Skye.

Puma Announces a Creative Deal to Unlock Value of its Assets in New Brunswick

Retrieved on: 
Monday, March 4, 2024

Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.

Key Points: 
  • Before the execution of the Raptor Agreements, Puma was holding a 100% interest in each of the Projects.
  • The sale of the Chester and Turgeon Projects to Raptor will allow Puma to further monetize its copper assets and unlock their value.
  • We’re always looking to increase shareholder value and creative ways to finance and control share dilution.
  • The objective for Puma is to receive from Raptor the same consideration value as the one that it negotiated in its initial option deal with Canadian Copper, of which CAD $2M remains receivable.

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Retrieved on: 
Monday, March 4, 2024

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has entered into a license and collaboration agreement with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.

Key Points: 
  • “We look forward to capitalizing on C4 Therapeutics’ experience in advancing degrader candidates targeting disease-causing proteins from discovery to the clinical stage, with the shared goal of improving patient outcomes.”
    Under the terms of the agreement, C4T and Merck KGaA, Darmstadt, Germany, will collaborate to discover two targeted protein degraders against critical oncogenic proteins.
  • C4T has the potential to receive up to approximately $740 million in discovery, regulatory, and commercial milestone payments across the collaboration.
  • As part of the collaboration, C4T will utilize its proprietary TORPEDO® platform to discover degraders targeting the partnership’s oncogenic proteins of interest.
  • Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.

AMPLITUDE, INC. (NASDAQ: AMPL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amplitude, Inc.

Retrieved on: 
Monday, March 4, 2024

If you purchased or acquired Amplitude common stock, and/or would like to discuss your legal rights and options please visit Amplitude, Inc.

Key Points: 
  • If you purchased or acquired Amplitude common stock, and/or would like to discuss your legal rights and options please visit Amplitude, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 15, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

Retrieved on: 
Friday, March 1, 2024

Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."

Key Points: 
  • Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."
  • Dr. Sarel joins a prestigious lineup of speakers including representatives from leading exosome companies, e.g.
  • The summit will take place on April 23-25, 2024 in Boston, MA.
  • To learn more about the summit and to register, please visit the Conference Website .

Boralex posts record net earnings of $115 million for 2023 and increases its financial flexibility, with nearly $550 million in available cash resources and authorized financing1 to support its growth

Retrieved on: 
Friday, March 1, 2024

MONTREAL, March 01, 2024 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) is pleased to report a significant increase in earnings in the fourth quarter of 2023 and for fiscal 2023 overall.

Key Points: 
  • Operating income of $98 million ($119 million) in Q4-2023 and $226 million ($306 million) for fiscal 2023.
  • Net earnings of $58 million in Q4-2023 and $115 million for fiscal 2023, compared to a net loss of $7 million in Q4-2022 and net earnings of $8 million for fiscal 2022.
  • Net cash flows related to operating activities of $107 million in Q4-2023 and $496 million in fiscal 2023.
  • Boralex has $547 million in available cash resources and authorized financing facilities2 as at December 31, 2023, up $155 million from the previous quarter.